GSK says new data buoys Jemperli as a treatment for rectal cancer
https://seekingalpha.com/news/4112388-gsk-says-new-data-buoys-jemperli-treatment-rectal-cancer?source=feed_sector_healthcare
Jun 03, 2024 - GSK's Jemperli (dostarlimab) is a potential alternative to surgery for rectal cancer patients, according to new phase 2 data. Read more here.
0
GSK says Blenrep combo cuts disease progression, death in multiple myeloma
https://seekingalpha.com/news/4112369-gsk-says-belnrep-combo-cuts-disease-progression-death-multiple-myeloma?source=feed_sector_healthcare
Jun 03, 2024 - GSK's Blenrep combination therapy reduces disease progression or death risk by nearly 50% compared to J&J's Velcade combo according to new data. Read more here.
0
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
https://www.zacks.com/stock/news/2282848/gsk-stock-dips-on-delaware-court-ruling-for-zantac-litigation?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282848
Jun 03, 2024 - GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
0
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
https://www.zacks.com/stock/news/2282785/moderna-mrna-secures-fda-nod-for-mrna-based-rsv-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282785
Jun 03, 2024 - The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
0
Is Moderna Stock a Buy Now That It's a 2-Product Company?
https://www.fool.com/investing/2024/06/03/is-moderna-stock-a-buy-now-that-its-a-2-product-co/?source=iedfolrf0000001
Jun 03, 2024 - The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.
0
FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
https://www.cnbc.com/2024/05/31/fda-approves-moderna-rsv-vaccine-for-seniors.html
May 31, 2024 - The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2278560/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2278560
May 24, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
https://www.zacks.com/stock/news/2278671/the-zacks-analyst-blog-highlights-biogen-ionis-pharmaceuticals-gsk-ptc-therapeutics-and-larimar-therapeutics?cid=CS-ZC-FT-press_releases-2278671
May 24, 2024 - Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
0
GSK wins first Zantac cancer jury trial (updated)
https://seekingalpha.com/news/4109935-gsk-wins-first-zantac-cancer-jury-trial?source=feed_sector_healthcare
May 23, 2024 - A Chicago jury dismisses a woman's claim that Zantac caused her colon cancer. Read more here.
0
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
https://www.zacks.com/stock/news/2278232/biotech-stock-roundup-biib-s-acquisition-ptct-lrmr-gain-on-updates-more-news?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2278232
May 23, 2024 - Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
0